Background: Hepatopancreaticoduodenectomy (HPD) is one of the most complex procedures, and it is very rarely reported. Laparoscopic HPD (LHPD) is even rarer. To date, there are only 3 reports of LHPD for locally advanced gallbladder cancer (GBC) or extrahepatic cholangiocarcinoma (ECC). This is the first report of LHPD for synchronous GBC and ECC.
Case Presentation: A 75-year-old female patient complained of jaundice for 2 weeks without fever or abdominal pain. She was diagnosed with synchronous GBC and ECC. After a comprehensive preparation, she underwent a laparoscopic pancreaticoduodenectomy and resection of hepatic segments of IVb and V, and her digestive tract reconstruction followed Child's methods. She was discharged on the 12th day postoperatively without pancreatic leakage, biliary leakage, or liver failure.
Conclusions: LHPD is safe and feasible for selected cases of GBCs or ECCs.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178805 | PMC |
http://dx.doi.org/10.1186/s12957-022-02628-9 | DOI Listing |
Aliment Pharmacol Ther
January 2025
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Gallbladder cancer (GBC) is a highly lethal and often overlooked malignancy increasingly affecting young adults. This study quantified the global proportion of GBC cases attributable to 10 key modifiable risk factors, employing Monte Carlo simulations and estimates from field-wide systematic review and meta-analysis. Approximately three-quarters of global GBC cases are attributable to key modifiable factors (74.
View Article and Find Full Text PDFCureus
December 2024
Anesthesiology, Tata Main Hospital, Jamshedpur, IND.
Biomarkers have the potential to play a crucial role in managing gallbladder cancer post-surgery. They can identify patients more likely to experience a recurrence, allowing oncologists to tailor a more intensive surveillance plan and consider additional therapies. Some biomarkers can even predict how well a patient will respond to specific chemotherapy or targeted treatments.
View Article and Find Full Text PDFCancer Diagn Progn
January 2025
Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan.
Background/aim: The incidence of biliary tract cancers (BTC), including cholangiocarcinoma and gallbladder cancer, has been increasing worldwide. Approximately 70% of BTC patients have advanced disease at diagnosis, leading to a poor survival rate. Recent clinical trials have demonstrated that the addition of immune checkpoint inhibitors, such as durvalumab or pembrolizumab, to gemcitabine plus cisplatin chemotherapy significantly improves survival rates, making triple therapy the current standard for first-line treatment of BTC.
View Article and Find Full Text PDFPathol Res Pract
December 2024
Research Fellow School of Life Sciences, University of Sussex, Brighton, UK. Electronic address:
Humans have more than 270,000 lncRNAs. Among these, lncRNA HOXA-AS2 is considered a transformative gene involved in various cellular processes, including cell proliferation, apoptosis, migration, and invasion. Thus, it can be regarded as a potential tumor marker for both diagnosis and prognosis.
View Article and Find Full Text PDFMutat Res
December 2024
School of Health Sciences and Technology, UPES, Dehradun, Uttarakhand 248007, India. Electronic address:
Gallbladder cancer (GBC) is an aggressive malignancy with a poor prognosis, often diagnosed at advanced stages due to subtle early symptoms. Recent studies have provided a comprehensive view of GBC's genetic and mutational landscape, uncovering crucial pathways involved in its pathogenesis. Environmental exposures, particularly to heavy metals, have been linked to elevated GBC risk.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!